Despite the limits of our preclinical experimental study, and avoiding any simplistic extrapolation of data from the animal model to the human condition, the results of this research suggest that the pharmacological modulation of PDIA3 may have an important impact on the onset and/or progression of AD. This evidence concerns the gene PDIA3 and Alzheimer disease.